The expression and signaling of FGFR3 in WM cells.

Slides:

Advertisements

Similar presentations

Glioma-derived soluble factor(s) enhance IL-10 signaling.

Advertisements

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Rearrangements of Gene A and Gene B

Oncogenic B-Raf mutations

Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

ILK knockdown decreases mTOR signaling in PKD kidneys.

Pi and FGF2 differentially activate the FGFR1-FRS2α-ERK pathway.

A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.

Leukemic blasts express a “hypoxia signature

FAK overexpression in invasive human breast cancer and DCIS

G3139 substitutes for heparin, which is required for the biological activity of FGF2. G3139 substitutes for heparin, which is required for the biological.

FAK overexpression in invasive human colon cancer and colon dysplasia.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

CLL-1 expression in patients with AML and normal donors.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Binding and internalization of bispecific immunotoxins.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

IGF-IR in human head and neck cancer.

AMs contribute to the progression of EGFR-mutant lung adenocarcinoma.

Expression of XCR1 in normal ovarian surface epithelium and the IOSE and borderline EOC cell lines. Expression of XCR1 in normal ovarian surface epithelium.

Immunologic and pharmacokinetic studies.

PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Distribution of FGFR aberrancies in urothelial cancers.

Reduced klotho expression in pancreatic cancer.

Correlations of the breast cancer hypoxia metagene with Ki67 and the proliferation metagene. Correlations of the breast cancer hypoxia metagene with Ki67.

Adhesion to fibronectin protects Mcl-1 knockdown cells from apoptosis.

Increased apoptotic levels after combined treatment with vincristine (VCR) and imatinib. Increased apoptotic levels after combined treatment with vincristine.

Increased apoptotic levels after combined treatment with DXR and imatinib. Increased apoptotic levels after combined treatment with DXR and imatinib. A–D.

Prevalence of germline T790M.

Kaplan–Meier curves for RFS and OS by various marker groups.

ODC protein expression in paired benign and cancer tissue obtained from patients with PCA. The protein expression was measured by immunoblot analysis in.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

ROC analysis of MIC-1 and CA19-9.

Immunoblot analysis in PANC1 and MSTO-211H cells.

DFS and DSS curves according to low, intermediate, and high stromal CD8+ T-cell density in the four different cohorts; A and B, University Hospital of.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

CpG oligodeoxynucleotide (CpG ODN)–induced activation of different types of primary malignant B cells. CpG oligodeoxynucleotide (CpG ODN)–induced activation.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. A,

Effect of MIF siRNA on the production of MMP-13 induced by LPA

W. chinensis extract induces apoptosis in AR-dependent prostate cancer cells. W. chinensis extract induces apoptosis in AR-dependent prostate cancer cells.

Detection of E-cadherin fragments in human prostate cancer metastases.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Expression of chemokine receptors in A-498 cell line.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

Representative images for different populations of detected cells in prostate cancer patients and five rounds of FISH in a CTC. A, Immunofluorescence image.

LY elicits hyperphosphorylation of Akt.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

Fig. 3. Association between peak CTL019 expansion and response.

CD36 expression in tissue adjacent and distal to the tumor.

Quantitative PCR (A) and Western blot (B) analyses for expression of CD133 and ALDH isoforms in CD133+ and CD133− cells sorted from HCC cell lines PLC8024.

MDSC population in patient peripheral blood.

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Presentation transcript:

The expression and signaling of FGFR3 in WM cells. The expression and signaling of FGFR3 in WM cells. A, the expression of FGFR3 (green; FITC, blue: DAPI) in CD19+ cells from WM patients and normal subjects detected by immunoflourescence. B, expression of FGFR3 in CD19+ cells from patients with WM (N = 6), normal subjects (N = 2), and cell lines (BCWM.1 and MEC-1) detected by flow cytometry. C, the activation of FGFR3 by FGF3 detected by increased phosphorylation of FGFR3, RAF, ERK, and STAT3 with maximal activation at 30 minutes after addition of FGF3. Abdel Kareem Azab et al. Clin Cancer Res 2011;17:4389-4399 ©2011 by American Association for Cancer Research